Team science and the creation of a novel rotavirus vaccine in India: a new framework for vaccine development

In The Lancet, findings from Nita Bhandari and colleagues' phase 3 clinical trial show the safety and efficacy of the 116E rotavirus vaccine against severe rotavirus gastroenteritis in Indian infants. The vaccine has an efficacy similar to that of two licensed oral rotavirus vaccines—RotaTeq (Merck) and Rotarix (GlaxoSmithKline)—when tested in low-income settings. However, the timeline of development has been unique and unconventional. The vaccine was not the product of a major multinational manufacturer, but rather, the result of work by team science, based in India (read more)